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Abstract
 Cyclin-dependent kinase inhibitor 1C (CDKN1C) is a keyBackground:
negative regulator of cell growth encoded by a paternally
imprinted/maternally expressed gene in humans. Loss-of-function variants
in   are associated with an overgrowth conditionCDKN1C
(Beckwith-Wiedemann Syndrome) whereas “gain-of-function” variants in 
that increase protein stability cause growth restriction as part ofCDKN1C 
IMAGe syndrome ( ntrauterine growth restriction,  etaphyseal dysplasia, I M A
drenal hypoplasia and  nital anomalies). As two families have beenGe
reported with   mutations who have fetal growth restrictionCDKN1C
(FGR)/Silver-Russell syndrome (SRS)   adrenal insufficiency, wewithout
investigated whether pathogenic variants in   could be associatedCDKN1C
with isolated growth restriction or recurrent loss of pregnancy.
 Analysis of published literature was undertaken to review theMethods:
localisation of variants in   associated with IMAGe syndrome orCDKN1C
fetal growth restriction.   expression in different tissues wasCDKN1C
analysed in available RNA-Seq data (Human Protein Atlas). Targeted
sequencing was used to investigate the critical region of   forCDKN1C
potential pathogenic variants in SRS (n=58), FGR (n=26), DNA from
spontaneous loss of pregnancy (n= 21) and women with recurrent
miscarriages (n=71) (total n=176).
 All published single nucleotide variants associated with IMAGeResults:
syndrome are located in a highly-conserved “hot-spot” within the
PCNA-binding domain of CDKN1C between codons 272-279. Variants
associated with familial growth restriction but normal adrenal function
currently affect codons 279 and 281.   is highly expressed in theCDKN1C
placenta compared to adult tissues, which may contribute to the FGR
phenotype and supports a role in pregnancy maintenance. In the patient
cohorts studied no pathogenic variants were identified in the PCNA-binding
domain of CDKN1C.
 CDKN1C is a key negative regulator of growth. Variants in aConclusion:
very localised “hot-spot” cause growth restriction, with or without adrenal
insufficiency. However, pathogenic variants in this region are not a common
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 very localised “hot-spot” cause growth restriction, with or without adrenal
insufficiency. However, pathogenic variants in this region are not a common
cause of isolated fetal growth restriction phenotypes or
loss-of-pregnancy/recurrent miscarriages.
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Introduction
Cyclin-dependent kinase inhibitor 1C (CDKN1C, also known 
as P57/kip2) (OMIM 600856) is a key negative regulator of 
cell proliferation that is encoded by a paternally imprinted 
(maternally expressed) gene on the short arm of chromosome 
11 (11p15.4) in humans (Stampone et al., 2018).
Consistent with its role in growth and development, maternally- 
inherited loss-of-function variants in CDKN1C are found in 
approximately 5–10% of individuals with the “overgrowth” 
condition, Beckwith-Wiedemann Syndrome (BWS) (OMIM 
130650) (Eggermann et al., 2014). Clinical features of BWS 
include macrosomia, hyperinsulinism and adrenal tumors.
In contrast, gain-of-function variants in CDKN1C have been 
shown to cause growth restriction as part of IMAGe syndrome 
(OMIM 614732) (Arboleda et al., 2012). IMAGe syndrome 
is characterised by fetal/Intrauterine growth restriction, Meta-
physeal dysplasia, Adrenal hypoplasia and Genital anomalies 
(in males, usually relatively mild hypospadias and undescended 
testes) as well as additional features such as hearing loss 
and hypercalciuria (Bennett et al., 1993; Vilain et al., 1999).
To date, children with IMAGe syndrome have all been found 
to harbour pathogenic single nucleotide variants (SNVs) 
in a very specific region of the PCNA-binding domain of 
CDKN1C (Arboleda et al., 2012; Cabrera-Salcedo et al., 2017). 
These changes potentially lead to increased activity through 
increasing protein stability, thereby preventing cell cycle 
progression into S phase (Borges et al., 2015; Hamajima et al., 
2013).
More recently, SNVs in the PCNA-binding domain of CDKN1C 
have been reported in families with maternally-inherited fetal 
growth restriction (FGR) without adrenal insufficiency and 
in familial Silver-Russell syndrome (SRS) (OMIM 180860) 
(Brioude et al., 2013; Kerns et al., 2014). SRS is character-
ised by variable clinical features including fetal and post-natal 
growth restriction, relative macrocephaly, feeding difficulties 
and characteristic facies. SRS is also described as phenotypi-
cally and genotypically opposite to BWS and approximately 
half of the molecular anomalies are attributed to Chr11p15.5 
imprinting clusters, including several individuals with 
maternal duplication of the locus containing CDKN1C 
(Bonaldi et al., 2011; Boonen et al., 2016; Schönherr et al., 2007). 
These findings suggest that the growth restriction phenotype 
associated with CDKN1C may be more variable and adrenal 
insufficiency is not always present.
The aim of this study was therefore to review published 
CDKN1C variants associated with FGR/IUGR phenotypes, to 
study CDKN1C expression in different tissues, and to analyse 
the critical region in CDKN1C in a range of growth restriction 
and adverse pregnancy phenotypes, with a hypothesis that severe 
restriction of feto-placental growth may, in some situations, 
result in pregnancy loss or recurrent miscarriage.
Methods
Review of pathogenic SNVs and population variability
A PubMed search was undertaken (March 2018) using the search 
terms “CDKN1C”, “human” and “growth”, or “IMAGe syn-
drome”. Reports focusing on growth restriction phenotypes 
associated with single nucleotide variants were considered. Pop-
ulation variation in CDKN1C was assessed using the gnomAD 
browser (http://gnomad.broadinstitute.org; accessed April 2018) 
(Lek et al., 2016). Protein conservancy analysis was performed 
using ClustalW in Jalview (Waterhouse et al., 2009).
Analysis of CDKN1C expression
RNA-Seq data for CDKN1C expression was obtained with 
specific permission from the Human Protein Atlas (Human 
Protein Atlas available from www.proteinatlas.org) and 
re-drawn in R (version 3.4.2) (Uhlen et al., 2015).
Study cohorts
The following growth restriction cohorts were included in this 
study: 1) SRS (n=58) (isolated, non-familial) diagnosed on 
consensus criteria and where maternal uniparental disomy or 
H19/IGF2:IG-DMR (also known as ICR1 or IC) hypomethyla-
tion had been excluded (Wakeling et al., 2017); 2) FGR (n=26) 
(isolated, non-familial) defined as birth weight less than the 
3rd centile, as part of the Baby Bio Bank cohort (UCL-GOS 
Institute of Child Health & St Mary’s Imperial College 
London) (Leon et al., 2016). Additional analysis was undertaken 
in DNA from 3) products of conception (POC) (n=21) where 
there had been a spontaneous loss of pregnancy and 4) mothers 
who had a history of recurrent miscarriages (n=71) (at least 
three miscarriages) where an underlying cause was not known 
(Baby Bio Bank). An overview of these cohorts is provided in 
Table 1.
Table 1. Overview of the cohorts studied.
Cohort Number Characteristics Sequencing
Silver-Russell 
Syndrome
58 Silver-Russell syndrome; maternal uniparental disomy of chromosome 7 or 
H19/IGF2:IG-DMR hypomethylation excluded
Sanger
IUGR/FGR 26 DNA from children with intra-uterine growth restriction (birth weight < 3rd 
percentile) (Baby Bio Bank)
Next-generation sequencing 
(mean read depth 37.8)
Products of 
conception
21 DNA from lost products of conception between 9–11 weeks gestation Next-generation sequencing 
(mean read depth 60.1)
Recurrent 
miscarriages
71 DNA from mothers with recurrent miscarriages (>3) and usually a history of 
live births
Next-generation sequencing 
(mean read depth 31.5)
Abbreviations: FGR, fetal growth restriction; IUGR, intrauterine growth restriction
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Consent
Ethical Committee approval for the Baby Bio bank was obtained 
from the Trent Derby Ethics Committee (09/H0405/30) and 
Ethical Committee approval for the Silver Russell trios was 
from GOSH Research Ethics Committee (REC No. 1278). 
Written informed consent was obtained from participants or 
parents. DNA was extracted from blood lymphocytes, placental 
tissue or products of conception, as appropriate.
Genomic analysis of CDKN1C by Sanger Sequencing
Direct Sanger Sequencing was undertaken for SRS patients 
to analyse the PCNA-binding region (codons 213–316) and 
hotspot (codons 272–281) using primers reported previously 
(CCDS7738, ENST00000414822.8) (Arboleda et al., 2012). Addi-
tional primers pairs were used to sequence the 3’ end of exon 1 
and splice site (CDKN1CF: CAGGAGCCTCTCGCTGAC; 
CDKN1CR2: GCTGGAGGGCACAACAAC). Polymerase chain 
reaction (PCR) was carried out with BIOTAQ DNA Polymer-
ase (BIOLINE, London, UK). PCR products were purified by 
microclean (Microzone, Haywards Heath, UK) and amplified 
with BigDyeTerminator v1.1, followed by sequencing on 
a DNA Analyzer 3070 (Applied Biosystems, California, US). 
The resulting read-outs were reviewed in Sequencher (v5.3: 
Gene Codes).
Genomic analysis of CDKN1C by targeted capture array 
and next generation sequencing
Targeted array capture followed by next-generation sequencing 
was performed for FGR samples, products of conception 
and mothers with a history of recurrent miscarriage.
A targeted enrichment custom HaloPlex 501kb–2.5Mb HS 
panel (Agilent Technologies Inc.) was designed using Agilent 
SureDesign to capture known and candidate genes for fetal 
growth disruption, including CDKN1C. This study used designs 
targeting either 147 (design size 1.391 Mbp) or 257 (design size 
2.045 Mbp) genes.
Sequencing libraries were prepared using 50ng of genomic 
DNA following the manufacturer’s protocol (HaloPlex HS 
Target Enrichment System for Illumina Sequencing version 
C1 from December 2016) and as described in principle previ-
ously (Guran et al., 2016). This was followed by 2 x 100bp or 
2 x 149bp paired end sequencing to a median read depth of 
300x on a NextSeq sequencer (Illumina Inc.). The bcl files were 
converted to fastq files using manufacturers recommended 
guidelines and were then analysed in SureCall software (ver-
sion 4.0.1.46 (Agilent Technologies) using the HaloPlex Default 
Method or custom settings (minimum number of read pairs 
per barcode =1). Samples with a minimum read depth less 
than 4 at any single nucleotide position were excluded.
Results
Single nucleotide variants in CDKN1C
Review of available data revealed six publications describing 
isolated individuals (7) or families (4) with IMAGe syndrome 
and adrenal insufficiency, who had pathogenic variants in a key 
region of the PCNA-binding domain of CDKN1C affecting 
codons 272, 274, 276, 278 and 279 (Figure 1, Table 2) (Arboleda 
et al., 2012; Bodian et al., 2014; Brioude et al., 2013; 
Hamajima et al., 2013; Kato et al., 2014; Kerns et al., 2014). 
These codons are highly conserved amongst species (Figure 2). 
Multiple individuals from different ancestral backgrounds 
were found to have p.Asp274Asn or p.Lys278Glu changes.
Variants in CDKN1C associated with familial Silver-Russell 
syndrome or growth restriction but normal adrenal function were 
Figure 1. Schematic diagram showing the structure of CDKN1C and the clustering of pathogenic variants associated with IMAGe 
syndrome and/or growth restriction.
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Table 2. Reported variants in CDKN1C and associated phenotypes.
Nucleotide 
variant
Protein change Isolated/Familial Phenotype Reference
c.815T>G p.Ile272Ser Familial (3) IMAGe Hamajima et al., 2013
c.820G>A p.Asp274Asn Isolated IMAGe Arboleda et al., 2012
c.820G>A p.Asp274Asn Isolated IMAGe Kato et al., 2014
c.820G>A p.Asp274Asn Isolated IMAGe (Glucocorticoid) Kato et al., 2014
c.826T>G p.Phe276Val Familial (7) IMAGe Arboleda et al., 2012
c.827T>C p.Phe276Ser Isolated IMAGe Arboleda et al., 2012
c.832A>G p.Lys278Glu Isolated IMAGe Arboleda et al., 2012
c.832A>G p.Lys278Glu Isolated IMAGe (Mineralocorticoid) Bodian et al., 2014
c.836G>C p.Arg279Pro Isolated IMAGe Arboleda et al., 2012
c.836G>T p.Arg279Leu Familial (9) Silver-Russell Brioude et al., 2013
c.842G>T p.Arg281Ile Familial (15) IUGR, short stature, 
IGT/DM
Kerns et al., 2014
Abbreviations: DM, diabetes mellitus; IGT, impaired glucose tolerance; IMAGe, intrauterine growth restriction, 
metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies; IUGR, intrauterine growth restriction
Figure 2. Amino-acid conservancy in the “hot-spot” region of CDKN1C. Red arrowheads represent codons that are mutated in IMAGe 
syndrome, FGR/IUGR or Silver-Russell syndrome. Yellow asterisks represent complete conservation amongst the species shown.
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found towards the carboxyl-terminal region of this “hot-spot” 
domain (p.Arg279Leu, p.Arg281Ile) (Figure 1).
Analysis of population data from the gnomAD browser 
showed a complete absence of variants in the key codons 
listed. Very rare heterozygous SNVs were found that are pre-
dicted to cause p.Ala277Val (11:2905355G>A;1 in 107288 
alleles) and p.Ala283Val (11:2905337G>A; rs776541692; 1 in 
30726 alleles) changes. Of note, these codons are two of the 
lesser-conserved amino acids within this “hot-spot” region 
(Figure 2).
Expression of CDKN1C in human tissue
RNA-Seq analysis of CDKN1C in a panel of human 
tissues showed highest expression in the placenta (Figure 3; 
Human Protein Atlas data, https://www.proteinatlas.org/
ENSG00000129757-CDKN1C/tissue), with strong expression also 
in adipose tissue, ovary, adrenal, endometrium and kidney. Immu-
nohistochemistry in the Human Protein Atlas repository shows 
strong staining in the nuclei of both decidual and trophoblastic 
cells (https://www.proteinatlas.org/ENSG00000129757-CDKN1C/
tissue/placenta).
Analysis of CDKN1C variants in growth restriction
Analysis of the PCNA-binding domain of CDKN1C by Sanger 
sequencing in a cohort of 58 children with isolated (non- 
familial) Silver-Russell syndrome did not reveal any pathogenic 
variants. Sequencing data for exon 2 is shown in Supplementary 
Data 1 (Achermann, 2018).
A next-generation sequencing approach of CDKN1C in 
children with IUGR/FGR (n=26), products of conception (n=21), 
and mothers with a history of recurrent miscarriage (n=71) 
also did not reveal pathogenic variants in this region (Table 1). 
Details of coverage for each sample/cohort and each nucleotide 
is shown in Supplementary Data 2–7 (Achermann, 2018).
Discussion
CDKN1C is now well-established as a key regulator of cell 
cycle and growth through G1 phase cell cycle arrest. Although 
loss-of-function of CDKN1C is known to cause macrosomia 
as part of Beckwith-Wiedemann Syndrome, it is only in the 
past six years that “gain-of-function” variants in CDKN1C have 
been shown to cause growth restriction and IMAGe syndrome. 
These findings demonstrate clearly how opposite effects in 
protein function can have opposite phenotypes (Arboleda 
et al., 2012; Eggermann et al., 2014). Sometimes these features 
affect not just growth but also endocrine systems (e.g. adrenal 
tumours (BWS)/adrenal hypoplasia (IMAGe); congenital hyper-
insulinism (BWS)/diabetes mellitus (one family with growth 
restriction)).
Review of published literature confirms that CDKN1C SNVs 
associated with IMAGe syndrome or growth restriction are all 
located within a “hot-spot” of the PCNA-binding domain of 
the protein. The exact function of this region is not clear, and 
the crystal structure of this region of CDKN1C has not yet 
been solved. Studies to date suggest pathogenic variants may 
increase protein stability or reduce the rate of degradation, 
thereby enhancing the negative effects of CDKN1C on cell cycle 
Figure 3. RNA expression of CDKN1C in placenta and different adult human tissues. Data reproduced and modified with permission 
from the Human Protein Atlas (www.proteinatlas.org) (Uhlen et al., 2015). TPM = Transcripts Per Million.
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progression (Borges et al., 2015; Hamajima et al., 2013). The 
very localised nature of these variants clearly demonstrates a key 
role for this region in CDKN1C function.
CDKN1C is strongly expressed in fetal adrenal development as 
shown by qPCR and immunohistochemistry (Arboleda et al., 
2012), by microarray (Del Valle et al., 2017), and RNA-Seq 
(unpublished). Furthermore, analysis of RNA-Seq data from 
the Human Protein Atlas shows marked expression in the pla-
centa (Figure 3). Immunohistochemistry shows strong nuclear 
staining in both decidual and trophoblastic cells. Therefore, 
gain-of-function of CDKN1C in the developing placenta could 
have a significant contribution to the growth restriction phenotype.
Further evidence for a potential role for CDKN1C in fetal 
growth restriction phenotypes has emerged with reports of 
CDKN1C variants in familial growth restriction and familial 
SRS (Brioude et al., 2013; Kerns et al., 2014). Several 
features of IMAGe syndrome and SRS overlap, such as 
bi-frontal bossing and relative micrognathia. To date these 
children have not shown evidence of adrenal insufficiency. 
Whilst a lack of adrenal features could be due to underlying 
mosaicism or a somatic “rescue” event, as recently reported 
for variants in SAMD9 in the related condition MIRAGE 
syndrome (Buonocore et al., 2017; Narumi et al., 2016), 
the fact that several individuals in a family with the same 
CDKN1C SNV were affected provides strong evidence that 
the primary genomic event is influencing the phenotype rather 
than a rescue mechanism. Of note, review of the two SNVs 
associated with FGR and normal adrenal function reveals 
that they affect amino acids at the C-terminal region of the 
hotspot. In one family a charged arginine at codon 279 is 
replaced by a non-polar leucine, whereas a proline at this 
position is found in classic IMAGe syndrome. In another family, 
the arginine at position 281 is replaced by a non-polar 
isoleucine. In some situations, variants in amino-acids flanking 
critical motifs can be associated with milder phenotypes 
(Kyriakakis et al., 2017).
Despite these findings, we did not identify any CDKN1C vari-
ants in children with isolated (non-familial) SRS or IUGR/
FGR. These results are similar to data from Brioude et al. 
who only reported a CDKN1C variant in familial SRS and 
did not find variants in 68 children with an isolated condition 
(Brioude et al., 2013). Whilst this does not exclude CDKN1C as a 
potential cause of isolated or sporadic SRS/FGR, it does suggest 
that it is not a common cause.
Identification of such strong expression of CDKN1C in the 
placenta lead us to consider whether gain-of-function/increased 
stability of CDKN1C could be associated with loss of preg-
nancy or recurrent miscarriage. This hypothesis was supported 
further by recent studies linking placental genes to pregnancy 
loss (Perez-Garcia et al., 2018); a potential role for placental 
CDKN1C expression in fetal growth and regulation by oestrogen 
(Chen et al., 2018; Gou et al., 2017; López-Abad et al., 2016; 
Unek et al., 2014); and the fact that paternal imprinting of the 
gene means that a pool of deleterious variants could be present 
in the population and cause pregnancy loss (together with live 
births) in women who carry this variant and inherit it from 
their father.
Analysis was therefore undertaken in a cohort of mothers 
who had recurrent miscarriages (often together with live 
birth(s)) and also from products of conception. However, no 
variants were found in the PCNA binding domain of CDKN1C in 
these cohorts.
This work has several limitations. Although 176 total individu-
als were studied, each sub group is still relatively small and rare 
CDKN1C variants might be discovered if the sample size is 
increased. The causes of recurrent miscarriage and fetal growth 
restriction are clearly diverse and can be influenced by many 
factors, and regulatory regions or enhancers (Perez-Garcia et al., 
2018; Rai & Regan, 2006; Stalman et al., 2018; Wakeling 
et al., 2017). Nevertheless, this study does highlight the role of 
the key region of CDKN1C in human fetal growth restriction 
phenotypes, and starts to address the potential role of single 
gene growth restriction phenotypes in more common obstetric 
and fetal conditions.
Data availability
Data has been uploaded to OSF: http://doi.org/10.17605/OSF.
IO/Y7KZV (Achermann, 2018). Representative sequencing 
data for chromatograms is shown in Supplementary Data 1. 
Data of coverage for next generation sequencing is shown 
in Supplementary Data 2–7.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Access for samples from the Baby Bio Bank is available and 
can be requested from the steering committee by emailing the 
Baby Bio Bank Manager (nita.solanky@ucl.ac.uk). More infor-
mation about data access can be found on the website under 
the ‘Protocol for the management of the Baby Bio Bank’, 
section 15: http://www.ucl.ac.uk/tapb/sample-and-data-collections- 
at-ucl/biobanks-ucl/baby-biobank/baby-biobank-documents/
BBB_SOP_version7. An application form for the use of Baby 
Bio Bank resources must be completed prior to application 
(see appendix 2 in the protocol).
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